Existing backers BBT Fund L.P. and SightLine Partners also participated in the round.
Minneapolis-headquartered CVRx’s main product is Barostim neo, an implantable system designed to treat hypertension and heart failure.
Barostim neo has received CE marking for the treatment of hypertension in Europe and it is currently under clinical evaluation for the treatment of heart failure in Europe and the US as well as for the treatment of hypertension in the US.
CVRx has treated more than 625 patients with its patented devices.
last month NEA co-led a $12.75m Series A financing round for SocialRadar alongside Grotech Ventures and SWaN & Legend Ventures.
Copyright © 2013 AltAssets